Zacks: Analysts Expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Will Announce Earnings of $0.50 Per Share

Equities analysts predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report earnings of $0.50 per share for the current quarter, according to Zacks. Eleven analysts have issued estimates for Neurocrine Biosciences’ earnings, with the highest EPS estimate coming in at $0.81 and the lowest estimate coming in at $0.04. Neurocrine Biosciences reported earnings per share of ($0.62) during the same quarter last year, which would suggest a positive year-over-year growth rate of 180.6%. The company is scheduled to report its next earnings results on Monday, November 8th.

According to Zacks, analysts expect that Neurocrine Biosciences will report full year earnings of $1.89 per share for the current financial year, with EPS estimates ranging from $0.91 to $2.67. For the next year, analysts expect that the company will post earnings of $3.64 per share, with EPS estimates ranging from $1.84 to $6.62. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Monday, August 2nd. The company reported $0.43 EPS for the quarter, missing analysts’ consensus estimates of $0.52 by ($0.09). Neurocrine Biosciences had a net margin of 35.34% and a return on equity of 33.04%. The business had revenue of $288.90 million for the quarter, compared to the consensus estimate of $274.47 million.

Several brokerages recently weighed in on NBIX. The Goldman Sachs Group assumed coverage on shares of Neurocrine Biosciences in a report on Tuesday, May 18th. They issued a “neutral” rating and a $108.00 price target on the stock. TheStreet lowered Neurocrine Biosciences from a “b-” rating to a “c+” rating in a research report on Monday, May 24th. Zacks Investment Research raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, August 18th. HC Wainwright reiterated a “buy” rating and issued a $140.00 price objective on shares of Neurocrine Biosciences in a report on Friday, July 16th. Finally, Canaccord Genuity lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $122.00 to $108.00 in a research note on Friday, August 6th. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Buy” and a consensus target price of $119.60.

In related news, insider Eric Benevich sold 5,628 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, August 16th. The stock was sold at an average price of $89.62, for a total transaction of $504,381.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Malcolm Lloyd-Smith sold 16,709 shares of the business’s stock in a transaction on Tuesday, July 27th. The stock was sold at an average price of $93.80, for a total value of $1,567,304.20. Following the completion of the transaction, the insider now directly owns 15,801 shares of the company’s stock, valued at $1,482,133.80. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio boosted its position in shares of Neurocrine Biosciences by 9.3% during the 1st quarter. Public Employees Retirement System of Ohio now owns 49,427 shares of the company’s stock valued at $4,807,000 after acquiring an additional 4,223 shares in the last quarter. Amundi Asset Management US Inc. lifted its position in shares of Neurocrine Biosciences by 10.0% during the first quarter. Amundi Asset Management US Inc. now owns 100,260 shares of the company’s stock worth $9,750,000 after purchasing an additional 9,151 shares in the last quarter. Nomura Asset Management Co. Ltd. lifted its holdings in Neurocrine Biosciences by 4.4% during the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 31,609 shares of the company’s stock worth $3,077,000 after buying an additional 1,327 shares in the last quarter. Brinker Capital Investments LLC boosted its holdings in Neurocrine Biosciences by 187.7% in the second quarter. Brinker Capital Investments LLC now owns 31,867 shares of the company’s stock valued at $3,101,000 after acquiring an additional 20,789 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Neurocrine Biosciences in the 1st quarter valued at about $10,752,000. 95.99% of the stock is currently owned by institutional investors.

NASDAQ NBIX traded up $1.42 during trading on Friday, hitting $96.04. The company’s stock had a trading volume of 2,087 shares, compared to its average volume of 900,142. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.21 and a quick ratio of 5.08. The business’s 50 day simple moving average is $94.07 and its 200-day simple moving average is $95.13. Neurocrine Biosciences has a fifty-two week low of $84.77 and a fifty-two week high of $120.27. The company has a market cap of $9.08 billion, a PE ratio of 25.44 and a beta of 0.73.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm’s product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W.

Further Reading: Moving Average (MA)

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.